The Female Sexual Function Index (FSFI) desire subscale has been criticized as lacking adequate breadth to fully evaluate women with Hypoactive Sexual Desire Disorder (HSDD) in treatment trials. Thus, we sought to identify the items that would constitute broadly important improvements. Lest multi-dimensional measures so identified increase the complexity of determining response, we also sought validated composite measures of HSDD, and to determine sensitive and specific responder and remitter criteria for such measures.
001 Composite Endpoints for Clinical Trials of Women with HSDD: Content, Responder Values, and Remitter Cutoffs
The Journal of Sexual Medicine